Vascular disrupting agents

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 2, 2007, Pages 605-615

  Lippert III, John W ^a  

^a ALBANY MOLECULAR RESEARCH INC   (United States)

Author keywords

Anticancer; Tubulin binding agents; Vascular disrupting agents; Vascular targeting agents

Indexed keywords

ANTINEOPLASTIC AGENT; AURISTATIN PE; CA 4P; CARBOPLATIN; CISPLATIN; COMBRETASTATIN A1 PHOSPHATE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOLASTATIN 10; DOXORUBICIN; FLAVONOID; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MELPHALAN; N ACETYLCOLCHINOL PHOSPHATE; OXALIPLATIN; OXI 2021; PACLITAXEL; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; VASCULAR TARGETING AGENT;

ANAPLASTIC CARCINOMA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ATAXIA; BLOOD FLOW; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SHAPE; CHEMOTHERAPY INDUCED EMESIS; CHROMATIN CONDENSATION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; CYTOSKELETON; DEPOLYMERIZATION; DIARRHEA; DNA DAMAGE; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SYNTHESIS; DYSPNEA; FATIGUE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPERTHERMIC THERAPY; HYPOTENSION; INFUSION ARM PAIN; ISCHEMIA; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; METASTASIS; MONOTHERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; OVARY CANCER; PAIN; PROSTATE CANCER; QT PROLONGATION; RADIOIMMUNOTHERAPY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLURRED SPEECH; SOFT TISSUE SARCOMA; SOLID TUMOR; SYNCOPE; THYROID CANCER; TREMOR; TUMOR NECROSIS; TUMOR VASCULARIZATION; URINE INCONTINENCE; UTERINE CERVIX CARCINOMA; VISUAL DISORDER;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; CARDIOVASCULAR AGENTS; FLAVONOIDS; HUMANS; NEOPLASMS; TERMINOLOGY; TUBULIN;

EID: 33845286942     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.10.020     Document Type: Review

References (146)

1. Thorpe P.E. Clin. Cancer Res. 10 (2004) 415
2. Denekamp J. Br. J. Cancer 45 (1982) 136
3. Denekamp J. Br. J. Radiol. 66 (1993) 181
4. Burrows F.J., Watanabe Y., and Thorpe P.E. Cancer Res. 52 (1992) 5954
5. Burrows F.J., and Thorpe P.E. Pharmacol. Ther. 64 (1994) 155
6. Burrows F.J., and Thorpe P.E. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8996
7. Hill S.A., Lonergan S.J., Denekamp J., and Chaplin D.J. Eur. J. Cancer 9 (1993) 1320
8. Hill S.A., Lonergan S.J., Denekamp J., and Chaplin D.J. Adv. Exp. Med. Biol. 345 (1994) 417
9. Siemann D.W., Bibby M.C., Dark G.G., Dicker A.P., Eskens F.A.L.M., Horsman M.R., Marme D., and LoRusso P.M. Clin. Cancer Res. 11 (2005) 416
10. Gaya A.M., and Rustin J.S. Clin. Oncol. 17 (2005) 277
11. Tozer G.M., Kanthou C., and Baguley B.C. Nat. Rev. Cancer 5 (2005) 423
12. Monk K.A., Siles R., Hadimani M.B., Mugabe B.E., Ackley J.F., Studerus S.W., Edvardsen K., Trawick M.L., Garner C.M., Rhodes M.R., Pettit G.R., and Pinney K.G. Bioorg. Med. Chem. 14 (2006) 3231
13. Tron G.C., Pirali T., Sorba G., Pagliai F., Busacca S., and Genazzani A.A. J. Med. Chem. 49 (2006) 3033
14. Siemann D.W., Chaplin D.J., and Horsman M.R. Cancer 100 (2004) 2491
15. Kelland L.R. Curr. Cancer Ther. Rev. 1 (2005) 1
16. Heeckeren W.J., Bhakta S., Ortiz J., Duerk J., and Cooney M.M. J. Clin. Oncol. 24 (2006) 1485
17. Oxigene. http://www.oxigene.com (accessed August 2006).
18. Chaplin D.J., and Hill S.A. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 1491
19. Chaplin D.J., and Dougherty G.J. Br. J. Cancer 80 (1999) 57
20. Horsman M.R., and Murata R. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 1518
21. Denekamp J. Cancer Metastasis Rev. 9 (1990) 267
22. Chaplin D.J., and Dougherty G.J. Br. J. Cancer 80 (1999) 57
23. Siemann D.W., Warrington K.H., and Horsman M.R. Radiother. Oncol. 57 (2000) 5
24. Hill S.A., Sampson L.E., and Chaplin D.J. Int. J. Cancer 63 (1995) 119
25. Chaplin D.J., Pettit G.R., Parkins C.S., and Hill S.A. Br. J. Cancer 74 (1996) S86
26. Dark G.D., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., and Chaplin D.J. Cancer Res. 57 (1997) 1829
27. Lash C.J., Li A.E., Rutland M., Baguley B.C., Zwi L.J., and Wilson W.R. Br. J. Cancer 78 (1998) 439
28. Horsman M.R., Ehrnrooth E., Ladekarl M., and Overgaard J. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 895
29. Rewcastle G.W., Atwell G.J., Zhuang L., Baguley B.C., and Denny W.A. J. Med. Chem. 34 (1991) 217
30. In Mosby's Medical, Nursing, and Allied Health Dictionary 3rd ed.; Como, D. N.; Sparks, L.; Dempsey, L. A., Eds.; The C. V. Mosby Company: St. Louis, Missouri, 1990; p 1204.
31. Siemann, D. W. Vascular Targeting Agents. In Horizons In Cancer Therapeutics From Bench to Bedside; Meniscus Educational Institute [online], 2002, Vol. 3, p 7.
32. Gobbi S., Rampa A., Bisi A., Belluti F., Valenti P., Caputo A., Zampiron A., and Carrara M. J. Med. Chem. 45 (2002) 4931
33. Gobbi S., Rampa A., Bisi A., Belluti F., Piazzi L., Valenti P., Caputo A., Zampiron A., and Carrara M. J. Med. Chem. 46 (2003) 3662
34. Philpott M., Ching L.M., and Baguley B.C. Eur. J. Cancer 37 (2001) 1930
35. Cao Z., Baguley B.C., and Ching L.M. Cancer Res. 61 (2001) 1517
36. Baguley B.C., Zhuang L., and Kestell P. Oncol. Res. (1997) 55
37. Zhou S., Kestell P., Baguley B.C., and Paxton J.W. Investig. New Drugs (1997) 55
38. Murta R., and Horsman M.R. Int. J. Hyperthermia 20 (2004) 393
39. Pruijn F.B., van Daalen M., Holford N.H., and Wilson W.R. Cancer Chemother. Pharmacol. 39 (1997) 541
40. Siemann D.W., Mercer E., Lepler S., and Rojiani A.M. Int. J. Cancer 99 (2002) 1
41. Sim B.G., Lee A.E., Shalal-Zwain S., Pruijn F.B., McKeage M.J., and Wilson W.R. Cancer Chemother. Pharmacol 51 (2003) 43
42. Pedley R.B., Boden J.A., Boden R., Boxer G.M., Flynn A.A., Keep P.A., and Begent R.H. Cancer Res. 56 (1996) 3293
43. Murata R., Siemann D.W., Overgaard J., and Horsman M.R. Radiat. Res. 156 (2001) 503
44. Wilson W.R., Li A.E., Cowan D.S., and Siim B.G. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 905
45. Kanwar J.R., Kanwar R.K., Pandey S., Ching L.M., and Krissansen G.W. Cancer Res. 61 (2001) 1948
46. Murata R., Overgaard J., and Horsman M.R. Int. J. Hyperthermia 17 (2001) 508
47. Horsman M.R., and Murata R. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 1518
48. Jameson, J. B.; Thompson, P. I.; Baguley, B. C.; Evans, B. D.; Harvey, V. J.; Porter, D. J.; McCrystal, M. R.; Small, M.; Bellenger, K.; Gumbrell, L.; Halbert, G. W.; Kestell, P.; Phase I/II Trials Committee of Cancer Research UK. Br. J. Cancer, 2003, 88, 1844.
49. U.S. Clinical Trials. http://clinicaltrials.gov/ct/show/NCT00111618?order=1 (accessed August 2006).
50. Antisoma. http://www.antisoma.com/media_room/pressrelease.asp (accessed August 2006).
51. Zheng Y. Annu. Rev. Cell Dev. Biol. 20 (2004) 867
52. Krendel M., Zenke F.T., and Bokoch G.M. Nat. Cell Biol. 4 (2002) 294
53. Zenke F.T., Krendel M., DerMardirossian C., King C.C., Bohl B.P., and Bokoch G.M. J. Biol. Chem. 279 (2004) 18392
54. Burridge K., and Vennerberg K. Cell. 116 (2004) 167
55. Bayliss K.J., and Davis G.F. J. Biol. Chem. 279 (2004) 11686
56. Davis P.D., Dougherty G.J., Blakey D.C., Galbraith S.M., Tozer G.M., Holder A.L., Naylor M.A., Nolan J., Stratford M.R.L., Chaplin D.J., and Hill S.A. Cancer Res. 62 (2002) 7247
57. Micheletti G., Poli M., Borsotti P., Martinelli M., Imberti B., Taraboletti G., and Giavazzi R. Cancer Res. 63 (2003) 1534
58. Cech J., and Santavy F. Collect. Czech. Chem. Commun. 4 (1949) 532
59. Evelhoch J.L., LoRusso P.M., He Z., DelProposto Z., Polin L., Corbett T.H., Langmuir P., Wheeler C., Stone A., Leadbetter J., Ryan A.J., Blakey D.C., and Waterton J.C. Cancer Res. 10 (2004) 3650
60. Goto H., Yano S., Zhang H., Matsumori Y., Ogawa H., Blakey D.C., and Sone S. Cancer Res. 62 (2002) 3711
61. Blakey D.C., Westwood F.R., Walker M., Hughes G.D., Davis P.D., Ashton S.E., and Ryan A.J. Clin. Cancer Res. 8 (2002) 1974
62. Siemann D.W., and Rojiani A. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 1512
63. Davies, P. D.; Hill, S. A.; Galbraith, S. M.; et al. In Proceedings of the American Association for Cancer Research, 2000,. 41, 329.
64. Siemann D.W., and Rojiani A.M. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 164
65. Blakey D.C., Ashton S.E., Westwood F.R., Walker M., and Ryan A.J. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 1497
66. Gadgeel S.M., LoRusso P.M., Wozniak A.J., and Wheeler C.A. Proc. Am. Soc. Clin. Oncol. 21 (2002) 110a abstract 438. Reference 23 p. 19
67. U.S. Clinical Trials. http://clinicaltrials.gov/ct/show/NCT00065572?order=1 (accessed August 2006).
68. U.S. Clinical Trials. http://clinicaltrials.gov/ct/show/NCT00065117?order=2 (accessed August 2006).
69. AstraZeneneca. http://www.astrazeneca.com/sites/7/imagebank/typeArticleparam511672/astrazeneca-2005-annual-report.pdf (accessed August 2006).
70. Pettit G.R., Srirangam J.K., Barkoczy J., Williams M.D., Durkin K.P.M., Boyd M.R., Bai R., Hamel E., Schmidt J.M., and Chapuis J.C. Anti-Cancer Drug Des. 10 (1995) 529
71. Pettit, G. R.; Barkoczy, J. (Arizona State Univ.) EP 600745, JP 95002894. Compound 22 in Scheme 4 is a synthetic intermediate (see the above references).
72. Alternative synthetic method for TZT1027. Miyazaki K., Kobayashi M., Natsume T., Gondo M., Mikami T., Sakakibara K., and Tsukagoshi S. Chem. Pharm. Bull. 43 (1995) 1706
73. Sakakibara, K.; Gondo, M.; Miyazaki, K. (Teikoku Hormone Mfg. Co., Ltd) EP 598129, JP 93503479, US 5654399, WO 9303054.
74. Hoshi A., Leeson P., and Castaner J. Drugs Future 24 (1999) 404
75. Schoffski P., Thate B., Beutel G., Bolte O., Otto D., Hofmann M., Ganser A., Jenner A., Cheverton P., Wanders J., Oguma T., Atsumi R., and Satomi M. Ann. Oncol. 15 (2004) 671
76. Natsume T., Watanabe J., Tamaoki S., Fujio N., Miyasaka K., and Kobayashi M. Jpn. J. Cancer Res. 91 (2000) 737
77. Kobayahi M., Natsume I., Tamaoki S., Watanabe J., Asano H., Mikami T., Miyasaka K., Masaaki G., Sakakibara K., and Tsukagoshi S. Jpn. J. Cancer Res. 88 (1997) 316
78. Watanabe J., Natsume N., Fujio N., Miyasaka K., and Kobayashi M. Apoptosis 5 (2000) 345
79. Natsume T., Kobayahi M., and Fujimoto S. Cancer 92 (2001) 386
80. Natsume T., Koh Y., Kobayshi M., Fukumoto H., Takahashi F., Nakamura T., Ohe Y., Saijo N., and Nishio K. Cancer Chemother. Pharmacol. 49 (2002) 35
81. Natsume T., Watanabe J., Koh Y., Fujio N., Ohe Y., Horiuchi T., Saijo N., Nishio K., and Kobayashi M. Cancer Sci. 94 (2003) 826
82. Ikeda R., Murakoshi M., Ohtani M., Tagawa M., Mikami T., Natsume T., Watanabe J., Kobayashi M., and Nakayama T. Acta Histochem. Cytochem. 33 (2000) 341
83. Otani M., Natsume T., Watanabe J., Kobayashi M., Murakoshi M., Mikami T., and Nakayama T. Jpn. J. Cancer Res. 91 (2000) 837
84. Hashiguchi N., Kubota T., Koh J., Yamada Y., Yoshiro S., Otani Y., Watanabe M., Kumai K., Kitajima M., Watanabe J., and Kobayashi M. Anticancer Res. 24 (2004) 2201
85. Jonge M.J.A., Gaast A., Planting A.S.T., Doorn L., Lems A., Boot I., Wanders J., Satomi M., and Verweij J. Clin. Cancer Res. 11 (2005) 3806
86. Natsume T., Watanabe J., Koh Y., Fujio N., Ohe Y., Horiuchi T., Nagahiro S., Nishio K., and Kobayashi M. Cancer Sci. 94 (2003) 826
87. U.S. Clinical Trials. http://www.clinicaltrials.gov/ct/show/NCT00064220?order=1 (accessed August 2006).
88. U.S. Clinical Trials. http://www.clinicaltrials.gov/ct/show/NCT00072228?order=2 (accessed August 2006).
89. U.S. Clinical Trials. http://www.clinicaltrials.gov/ct/show/NCT00061854?order=3 (accessed August 2006).
90. Japan's Corporate News. http://www.japancorp.net/Article.Asp?Art_ID=9972 (accessed August 2006).
91. Personal email correspondence with Dr. Motohiro Kobayashi of ASKA Pharmaceutical Co., Ltd (August 2006).
92. ASKA Pharmaceutical Co., Ltd http://www.aska-pharma.co.jp/english/corporate/history.html (accessed August 2006).
93. Pettit G.R., Singh S.B., Boyd M.R., Hamel E., Pettit R.K., Schmidt J.M., and Hogan F. J. Med. Chem. 38 (1995) 1666
94. Pettit G.R., and Rhodes M.R. Anticancer Drug Des. 13 (1998) 183
95. Pettit G.R., Temple Jr. C., Narayanan V.L., Varma R., Simpson M.J., Boyd M.R., Rener G.A., and Bansal N. Anticancer Drug Des. 10 (1995) 299
96. Dowlati A., Robertson K., Cooney M., Petros W.P., Stratford M., Jesberger J., Rafie N., Overmoyer B., Makkar V., Stambler B., Taylor A., Waas J., Lewin J.S., McCrae K.R., and Remick S.C. Cancer Res. 62 (2002) 3408
97. Griggs J., Metcalfe J.C., and Hesketh R. Lancet. Oncol. 2 (2001) 82
98. Brooks A.C., Kanthou C., Cook I.H., Tozer G.M., Barber P.R., Vojnovic B., Nash G.B., and Parkins C.S. Anticancer Res. 23 (2003) 3199
99. Tozer G.M., Prise V.E., Wilson J., Locke R.J., Vojnovic B., Stratford M.R., Dennis M.F., and Chaplin D.J. Cancer Res. 59 (1999) 1626
100. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., and Garcia-Kendall D. Experientia 45 (1989) 209
101. Woods J.A., Hadfield J.A., Pettit G.R., Fox B.W., and McGown A.T. Br. J. Cancer 71 (1995) 705
102. Tozer G.M., Kanthou C., Parkins C.S., and Hill S.A. Int. J. Exp. Pathol. 83 (2002) 21
103. Thomas C.D., Walczak C., Kaffy J., Pontikis R., Jouanneau J., and Volk A. Neoplasia 8 (2006) 587
104. Chaplin D.J., Pettit G.R., and Hill S.A. Anticancer Res. 19 (1999) 189
105. Chaplin D.J. Pathophysiol. Haemost. Thromb. 33 (2003) 9
106. Kanthou C., and Tozer G.M. Blood 99 (2002) 2060
107. Rojiani A.M., Li L., Rise L., and Siemann D. Acta Oncologica 41 (2002) 98
108. Tozer G.M., Prise V.E., Wilson J., Locke R.J., Vojnovic B., Stratford M.R.L., Dennis M.F., and Chaplin D.J. Cancer Res. 59 (1999) 1626
109. Li L., Rojiani A.M., and Siemann D.W. Acta Oncol. 41 (2002) 91
110. Grosios K., Loadman P.M., Swaine D.J., Pettit G.R., and Bibby M.C. Anticancer Res. 20 (2000) 229
111. Murata R., Overgaard J., and Horsman M. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 1018 Further reading on combination therapy with CA4P (34) is demonstrated in reference
112. Wiaam B., Kalliomaki S., Widegren B., and Sjoegren H.O. Clin. Cancer Res. 12 (2006) 4714
113. Rustin G.J.S., Galbraith S.M., Anderson H., Stratford M., Folkes L.K., Sena L., Gumbrell L., and Price P.M. J. Clin. Oncol. 21 (2003) 2815
114. U.S. Clinical Trials. http://clinicaltrials.gov/ct/show/NCT00113438?order=1 (accessed August 2006).
115. U.S. Clinical Trials. http://clinicaltrials.gov/ct/show/NCT00060242?order=2 (accessed August 2006).
116. U.S. Clinical Trials. http://clinicaltrials.gov/ct/show/NCT00077103?order=3 (accessed August 2006).
117. Pinney K.G., Jelinek C., Edvardsen K., Chaplin D.J., and Pettit G.R. In: Cragg G.M., Kingston D.G.I., and Newman D.J. (Eds). Anticancer Agents from Natural Products (2005), CRC Press, Boca Raton, Florida 23-46
118. Young S., and Chaplin D.J. Expert Opin. Investig. Drugs 13 (2004) 1171
119. Ohsumi K., Nakagawa R., Fukuda Y., Hatanaka T., Morinaga Y., Nihei Y., Ohishi K., Suga Y., Akiyama Y., and Tsuji T. J. Med. Chem. 41 (1998) 3022
120. Ohsumi K., Hatanaka T., Nakagawa R., Fukuda Y., Morinaga Y., Suga Y., Nihei Y., Ohishi K., Akiyama Y., and Tsuji T. Anti-Cancer Drug Design 14 (1999) 539
121. Hatanaka T., Fujita K., Ohsumi K., Nakagawa R., Fukuda Y., Nihei Y., Suga Y., Akiyama Y., and Tsuji T. Bioorg. Med. Chem. Lett. 8 (1998) 3371
122. Hori K., and Saito S. Br. J. Cancer 89 (2003) 1334
123. Nihei Y., Suzuki M., Okano A., Tsuji I., Akiyama Y., Tsuruo I., Saito S., Hori K., and Sato Y. Jpn. J. Cancer Res. 90 (1999) 1387
124. Hori K. Chemotherapy 51 (2005) 357
125. Hori K., and Saito S. Br. J. Cancer 90 (2004) 549
126. Nihei Y., Suga Y., Morinaga Y., Ohishi K., Okano A., Ohsumi K., Hatanaka T., Nakagawa R., Tsuji T., Akiyama Y., Saito S., Hori K., Sato Y., and Tsuruo T. Jpn. J. Cancer Res. 90 (1999) 1016
127. Hori K., Saito S., Nihei Y., Suzuki M., and Sato Y. Jpn. J. Cancer Res. 90 (1999) 1026
128. Hori K., Saito S., Sato Y., and Kubota K. Med. Sci. Monit. 7 (2001) 26
129. Ohno I., Kawano K., Sasaki A., Aramaki M., Tahara K., Etoh T., and Kitano S. Int. J. Clin. Oncol. 7 (2002) 171
130. Hori K., Saito S., Sato Y., and Kubota K. Br. J. Cancer 86 (2002) 1604
131. Hori K., Saito S., Sato Y., Akita H., Kawaguchi T., Sugiyama K., and Sato H. Euro. J. Cancer 39 (2003) 1957
132. For combination therapy discussion of AVE8062, see. Demers B., Vrignaud P., and Bissery M. J. Clin. Oncol. 24 (2006) 13074
133. Ajinomoto Co., Inc. http://www.ajinomoto.com/ar/i_r/releases/2001/01_07.html (accessed September 2006).
134. Aventis Pharmaceuticals Inc. http://www.AventisOncology.com (accessed September 2006).
135. Sanofi-Aventis. http://en.sanofi-aventis.com/rd/portfolio/p_rd_portfolio_oncology.asp (accessed September 2006).
136. Pettit G.R., and Lippert III J.W. Anti-Cancer Drug Design 15 (2000) 203
137. Pettit G.R., Singh S.B., Niven M.L., Hamel E., and Schmidt J.M. J. Nat. Prod. 50 (1987) 119
138. Kirwan I.G., Loadman P.M., Swaine D.J., Anthoney D.A., Pettit G.R., Lippert III J.W., Shnyder S.D., Cooper P.A., and Bibby M.C. Clin. Cancer Res. 10 (2004) 1446
139. Shnyder S.D., Cooper P.A., Pettit G.R., Lippert J.W., and Bibby M.C. Anticancer Res. 23 (2003) 1619
140. Bibby M.C., Cooper P.A., Holwell S.E., Lippert J.W., Martin S.W., Pettit G.R., and Thompson M.J. Anticancer Res. 22 (2002) 3933
141. Holwell S.E., Cooper P.A., Grosios K., Lippert J.W., Pettit G.R., Shnyder S.D., and Bibby M.C. Anticancer Res. 22 (2002) 707
142. Sheng Y., Hua J., Penny K.G., Garner C.M., Kane R.R., Prezioso J.A., Pettit G.R., Chaplin D.J., and Edvardsen K. Anticancer Res. 23 (2003) 1433
143. Sheng Y., Hua J., Pinney K.G., Garner C.M., Kane R.R., Prezioso J.A., Chaplin D.J., and Edvardsen K. Int. J. Cancer 111 (2004) 604
144. Kelland L.R. Curr. Cancer Ther. Rev. 1 (2005) 1
145. Salmon H.W., and Siemann D.W. Clinical Cancer Res. 12 (2006) 4090
146. Staflin K., Joarnum S., Hua J., Honeth G., Kannisto P., and Lindvall M. Int. J. Gynecol. Cancer 16 (2006) 1557